Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects

Ji-Young Park, Kyoung Ah Kim, Mun Ho Kang, Su Lyun Kim, Jae Gook Shin

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background and Objective: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone. Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans. Method: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with 600 mg rifampin or with placebo. On day 7, a single dose of 8 mg rosiglitazone was administered orally. Plasma rosiglitazone concentrations were measured. Results: Rifampin significantly decreased the mean area under the plasma concentration-time curve for rosiglitazone by 65% (2947.9 ng·h/mL versus 991.5 ng·h/mL, P < .001) and the mean elimination half-life from 3.9 to 1.5 hours (P < .001). The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P < .01). The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P < .001). Conclusion: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9. Therefore caution should be exercised during the coadministration of rifampin and rosiglitazone.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume75
Issue number3
DOIs
Publication statusPublished - 2004 Mar 1
Externally publishedYes

Fingerprint

rosiglitazone
Rifampin
Healthy Volunteers
Pharmacokinetics
Drug Interactions
Hypoglycemic Agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. / Park, Ji-Young; Kim, Kyoung Ah; Kang, Mun Ho; Kim, Su Lyun; Shin, Jae Gook.

In: Clinical Pharmacology and Therapeutics, Vol. 75, No. 3, 01.03.2004, p. 157-162.

Research output: Contribution to journalArticle

Park, Ji-Young ; Kim, Kyoung Ah ; Kang, Mun Ho ; Kim, Su Lyun ; Shin, Jae Gook. / Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. In: Clinical Pharmacology and Therapeutics. 2004 ; Vol. 75, No. 3. pp. 157-162.
@article{7c2beff993cf41369fb977eb594b2403,
title = "Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects",
abstract = "Background and Objective: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone. Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans. Method: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with 600 mg rifampin or with placebo. On day 7, a single dose of 8 mg rosiglitazone was administered orally. Plasma rosiglitazone concentrations were measured. Results: Rifampin significantly decreased the mean area under the plasma concentration-time curve for rosiglitazone by 65{\%} (2947.9 ng·h/mL versus 991.5 ng·h/mL, P < .001) and the mean elimination half-life from 3.9 to 1.5 hours (P < .001). The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P < .01). The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P < .001). Conclusion: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9. Therefore caution should be exercised during the coadministration of rifampin and rosiglitazone.",
author = "Ji-Young Park and Kim, {Kyoung Ah} and Kang, {Mun Ho} and Kim, {Su Lyun} and Shin, {Jae Gook}",
year = "2004",
month = "3",
day = "1",
doi = "10.1016/j.clpt.2003.10.003",
language = "English",
volume = "75",
pages = "157--162",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects

AU - Park, Ji-Young

AU - Kim, Kyoung Ah

AU - Kang, Mun Ho

AU - Kim, Su Lyun

AU - Shin, Jae Gook

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Background and Objective: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone. Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans. Method: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with 600 mg rifampin or with placebo. On day 7, a single dose of 8 mg rosiglitazone was administered orally. Plasma rosiglitazone concentrations were measured. Results: Rifampin significantly decreased the mean area under the plasma concentration-time curve for rosiglitazone by 65% (2947.9 ng·h/mL versus 991.5 ng·h/mL, P < .001) and the mean elimination half-life from 3.9 to 1.5 hours (P < .001). The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P < .01). The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P < .001). Conclusion: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9. Therefore caution should be exercised during the coadministration of rifampin and rosiglitazone.

AB - Background and Objective: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone. Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans. Method: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with 600 mg rifampin or with placebo. On day 7, a single dose of 8 mg rosiglitazone was administered orally. Plasma rosiglitazone concentrations were measured. Results: Rifampin significantly decreased the mean area under the plasma concentration-time curve for rosiglitazone by 65% (2947.9 ng·h/mL versus 991.5 ng·h/mL, P < .001) and the mean elimination half-life from 3.9 to 1.5 hours (P < .001). The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P < .01). The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P < .001). Conclusion: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9. Therefore caution should be exercised during the coadministration of rifampin and rosiglitazone.

UR - http://www.scopus.com/inward/record.url?scp=1542286164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542286164&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2003.10.003

DO - 10.1016/j.clpt.2003.10.003

M3 - Article

C2 - 15001966

AN - SCOPUS:1542286164

VL - 75

SP - 157

EP - 162

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -